A panel of outside advisers to the US health regulator backed GSK's respiratory syncytial virus vaccine, setting it up for a race with rival Pfizer to become the first approved US shot against the disease.
- A panel of outside advisers to the U.S. health regulator on Wednesday backed GSK Plc's respiratory syncytial virus vaccine, setting it up for a race with rival Pfizer to become the first approved U.S. shot against the disease.
The panelists seemed significantly more confident about the demographic profile used during the GSK study in comparison to Pfizer's RSV vaccine, which was recommended by the FDA panel on Tuesday. Pfizer and GSK are running a tight race to tap into the RSV vaccine market, which is estimated to be over $5 billion and could exceed $10 billion by 2030, according to analysts.
The FDA is scheduled to decide on the vaccines by May, and typically follows the recommendations of its independent panel of experts.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
US panel backs GSK vaccine, heating up RSV vaccine raceA panel of outside advisers to the U.S. health regulator on Wednesday backed GSK Plc's respiratory syncytial virus (RSV) vaccine, setting it up for a race with rival Pfizer to become the first approved U.S. shot against the disease.
Les mer »
Pfizer, GSK face FDA panel review in race for RSV vaccinesThe frontrunners in a crowded race to develop the first respiratory syncytial virus (RSV) vaccine - Pfizer Inc and GSK - will face scrutiny from a panel of experts to the U.S. Food and Drug Administration this week.
Les mer »
FDA Advisors Recommend GSK's RSV Vaccine for Older Adults, But Flag Potential Safety RisksA majority of the FDA panel said GlaxoSmithKline's RSV vaccine safety data was adequate and advisors were unanimous that the shot’s efficacy was good But some expressed concern that the shots could be associated with risks of rare nervous system disorders
Les mer »
FDA panel narrowly backs Pfizer's RSV vaccine for older adultsFederal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against...
Les mer »
U.S. FDA panel votes for Pfizer's RSV vaccineA panel of outside advisers to the U.S. Food and Drug Administration (FDA) on Tuesday recommended Pfizer Inc's respiratory syncytial virus (RSV) vaccine, paving the way for one of the first approved RSV shots in the United States for older adults.
Les mer »
FDA panel narrowly backs Pfizer RSV vaccine for older adultsFederal health advisers have narrowly backed an experimental vaccine from Pfizer that could become the first shot to protect older adults against the respiratory illness known as RSV.
Les mer »